Context: Introduction of highly active antiretroviral therapy has significantly decreased mortality in HIV-1-infected adults and children. Although an increase in non-HIV-related mortality has been noted in adults, data in children are limited.

Objectives: To evaluate changes in causes and risk factors for death among HIV-1-infected children in Pediatric AIDS Clinical Trials Group 219/219C.

Design, Setting, And Participants: Multicenter, prospective cohort study designed to evaluate long-term outcomes in HIV-1-exposed and infected US children. There were 3553 HIV-1-infected children enrolled and followed up between April 1993 and December 2006, with primary cause of mortality identified in the 298 observed deaths.

Main Outcome Measures: Mortality rates per 100 child-years overall and by demographic factors; survival estimates by birth cohort; and hazard ratios for mortality by various demographic, health, and antiretroviral treatment factors were determined.

Results: Among 3553 HIV-1-infected children followed up for a median of 5.3 years, 298 deaths occurred. Death rates significantly decreased between 1994 and 2000, from 7.2 to 0.8 per 100 person-years, and remained relatively stable through 2006. After adjustment for other covariates, increased risk of death was identified for those with low CD4 and AIDS-defining illness at entry. Decreased risks of mortality were identified for later birth cohorts, and for time-dependent initiation of highly active antiretroviral therapy (hazard ratio 0.54, P < 0.001). The most common causes of death were "End-stage AIDS" (N = 48, 16%) and pneumonia (N = 41, 14%). The proportion of deaths due to opportunistic infections (OIs) declined from 37% in 1994-1996 to 24% after 2000. All OI mortality declined during the study period. However, a greater decline was noted for deaths due to Mycobacterium avium complex and cryptosporidium. Deaths from "End-stage AIDS," sepsis and renal failure increased.

Conclusions: Overall death rates declined from 1993 to 2000 but have since stabilized at rates about 30 times higher than for the general US pediatric population. Deaths due to OIs have declined, but non-AIDS-defining infections and multiorgan failure remain major causes of mortality in HIV-1-infected children.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801894PMC
http://dx.doi.org/10.1097/QAI.0b013e3181b9869fDOI Listing

Publication Analysis

Top Keywords

hiv-1-infected children
20
mortality rates
8
death hiv-1-infected
8
children
8
highly active
8
active antiretroviral
8
antiretroviral therapy
8
mortality
8
mortality hiv-1-infected
8
3553 hiv-1-infected
8

Similar Publications

In 2023, we published a case study involving a 10-year-old HIV-1-infected child with low-level viremia (LLV). We showed that this child patient achieved successful viral suppression by modifying the antiretroviral therapy (ART) regimen according to the HIV-1 DNA genotypic drug resistance testing. In this study, we aimed to address whether HIV-1 DNA genotypic drug resistance testing could direct successfully virological suppression in HIV-1-infected patients experiencing persistent LLV based on evidence from a cohort study.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the envelope glycoprotein (Env) of HIV-1, which is essential for the virus's ability to infect host cells and is a key target for vaccines and therapies.
  • Researchers analyzed the genetic characteristics of the Env gene in 145 newly diagnosed HIV-1 patients in Baoding City, successfully sequencing 142 samples and predicting coreceptor usage.
  • Results indicated that 50% of the patients were infected with CCR5-tropic viruses, and specific subtypes showed trends in coreceptor preferences and similarities in the V3 loop's net charges, enhancing insights for vaccine and treatment development.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how co-occurring HIV and tuberculosis (TB) affect the heart's efficiency in adolescents with HIV acquired at birth (APHIV) in Cape Town, South Africa.
  • Researchers hypothesized that APHIV individuals who had previous TB would show worse cardiovascular health due to increased inflammation and disrupted metabolism.
  • Results indicated that APHIV with prior TB had lower cardiac efficiency compared to those without TB, but this was not linked to traditional markers of inflammation or lipid levels, suggesting other factors may be involved.
View Article and Find Full Text PDF

Background: Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and treatment-experienced children and adolescents remains poorly understood. In this study, we conducted a systematic review and meta-analysis to estimate the prevalence of HIVDR in these populations globally, regionally, and at the country level.

Methods: We systematically searched PubMed, Embase, and Web of Science for studies reporting HIVDR in treatment-naive and treatment-experienced children and adolescents from inception to June 28, 2024.

View Article and Find Full Text PDF

HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered "closed" conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC). CD4-mimetic compounds (CD4mcs) "open-up" Env allowing binding of CD4i nnAbs, thereby sensitizing HIV-1-infected cells to ADCC. Two families of CD4i nnAbs, the anti-cluster A and anti-coreceptor binding site (CoRBS) Abs, are required to mediate ADCC in combination with the indane CD4mc BNM-III-170.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!